New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Asklepios Kliniken · ISIN: DE000A0ETLQ3 · EQS - Company News (29 News)
Country: Germany · Primary market: Germany · EQS NID: 1640885
25 May 2023 10:00AM

Asklepios Kliniken:


EQS-News: Asklepios Kliniken / Key word(s): Quarterly / Interim Statement
Asklepios Kliniken:

25.05.2023 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Asklepios Group: Resilient business performance in Q1 2023

  • More than 850,000 patients cared for
  • Consolidated revenue amounts to EUR 1,341.8 million
  • Asklepios invests EUR 47.4 million of own funds

Hamburg, 25 May 2023. Asklepios Kliniken GmbH & Co. KGaA has made a resilient start to the first quarter of 2023. As such, Asklepios has established a sound basis for the 2023 financial year to counter the persistent inflation and the uncertainties arising from the planned hospital reform throughout Germany.

The Asklepios healthcare facilities cared for a total of 854,558 inpatients and outpatients in the first quarter of 2023 (3M 2022: 836,025). At EUR 1,341.8 million, revenue was up on the previous year’s figure (3M 2022: EUR 1,276.3 million).

In the first quarter, the cost of materials rose to EUR 345.8 million (3M 2022: EUR 321.5 million). The cost of materials ratio came to 25.8% in the first quarter of 2023 (3M 2022: 25.2%). The staff costs ratio was also higher than in the previous year at 68.9% (3M 2022: 68.0%). Absolute staff costs increased by EUR 57.2 million to EUR 924.9 million (3M 2022: EUR 867.7 million). The other expenses ratio came to 8.1% (3M 2022: 7.7%).

Overall, consolidated net income (EAT) for January to March 2023 amounted to EUR 9.2 million (3M 2022: EUR 6.4 million). The EAT margin was 0.7% (3M 2022: 0.5%).

Despite the difficult environment, Asklepios made high investments in its approximately 170 healthcare facilities. Investments including subsidies amounted to EUR 77.4 million. Internally financed capital expenditure increased by EUR 11.3 million to EUR 47.4 million in the first quarter of 2023 (3M 2022: EUR 36.1 million).

The Asklepios Group had a sound financial position in the first quarter of 2023: The ratio of net debt to EBITDA for the past 12 months was 3.4x (31 December 2022: 3.5x). Cash and cash equivalents amounted to EUR 661.1 million as at 31 March 2023 (31 December 2022: EUR 634.6 million).

In the 2023 financial year, the Asklepios Group anticipates a stable revenue performance, largely positive economic development and a slight, sustainable increase in EAT. Asklepios will react flexibly to external economic challenges and effectively handle changes in medical or regulatory requirements.

 

About Asklepios
Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has been developing dynamically since it was founded around 40 years ago. The Group currently has around 170 healthcare facilities throughout Germany. These include acute care hospitals of all different care levels, university hospitals, specialist clinics, psychiatric facilities, forensic institutions, rehabilitation clinics, nursing homes and medical centres. In the 2022 financial year, around 3.6 million patients were treated at the Asklepios Group’s facilities. The company has more than 67,000 employees.

IR contact
Mirjam Constantin
Head of Group ESG & Sustainability/ Manager Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 - 61462 Königstein-Falkenstein
Tel.: +49 61 74 90-1166
Fax: +49 61 74 90-1110
ir@asklepios.com

PR contact
Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 - 22307 Hamburg
Tel.: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639 
presse@asklepios.com

Visit Asklepios online, on Facebook or on YouTube:
www.asklepios.com
gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken



25.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1640885  25.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1640885&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.